Lobaplatin

Lobaplatin
Clinical data
Routes of
administration		IV Bolus Injections or Infusion
Identifiers
  • 1,2-diammino-methy lcyclobutane-platinum (II) lactate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H18N2O3Pt
Molar mass397.338 g·mol−1
Melting point220 °C (428 °F)
Solubility in water72.9 mg/mL (20 °C)

Lobaplatin is a platinum-based antineoplastic metallodrug approved exclusively in China for the treatment of small cell lung cancer, inoperable metastatic breast cancer and chronic myelogenous leukaemia.[1] The drug is a third-generation analogue of cisplatin, the first globally approved and widely used platinum-based anticancer drug.

Pharmacodynamics studies of lobaplatin found greater anticancer activity and lower toxicity than cisplatin and carboplatin, and showed activity against cisplatin-resistant cancer cells.[1] However, global approval of lobaplatin is restricted due to limited evidence of efficacy.

  1. ^ a b "Lobaplatin: D 19466". Drugs in R&D. 4 (6): 369–372. 2003. doi:10.2165/00126839-200304060-00008. PMID 14584968.